Medscape

Bioavailability of the Budesonide Delivered by the Clickhaler and Turbuhaler Dry Powder Inhalers in Healthy Volunteers: A Pilot Study

Objective: To compare the pharmacokinetic profile and bioavailability of budesonide after inhalation from the Clickhaler® dry powder inhaler with the Turbuhaler® as standard. Design: Randomised, ...
EurekAlert!

Results of the OPTIMA study show significant benefits from early and sustained treatment of mild asthma

Earlier and more sustained treatment of mild asthma improves control of asthma symptoms and reduces the risk of a severe exacerbation, thereby preventing lung function damage according to the results ...
Healio

As-needed budesonide-formoterol bests albuterol for exacerbation prevention in mild asthma

DALLAS — Single combination inhaler treatment with budesonide-formoterol on an as-needed basis, compared with albuterol, more than halved the risk for severe asthma attacks in patients with mild ...
Business Wire

Research and Markets: AstraZeneca's Pulmicort (Asthma) Treatment - Forecast and Market Analysis to 2023

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/bj53j9/pulmicort) has announced the addition of the "Pulmicort (Asthma ...
Pharmabiz

AstraZeneca’s Symbicort Turbuhaler receives China NMPA approval as an anti-inflammatory reliever in mild asthma

AstraZeneca’s Symbicort Turbuhaler (budesonide/formoterol 160/4.5mcg) has been approved in China as an anti-inflammatory reliever to be taken as-needed in response ...
PharmaTimes

AZ Symbicort reduces rate of asthma attacks

The results showed a a 51% reduction in the rate of annual asthma exacerbations compared to albuterol. AstraZeneca’s Novel START trial for its Symbicort Turbuhaler ...
PharmaTimes

Trials show benefit of ‘on demand’ use of AZ’ asthma inhaler

AstraZeneca has unveiled data from two Phase III trials showing the benefit of using Symbicort Turbuhaler as an anti-inflammatory reliever ‘as needed’ versus two different treatment regimens in ...
Europa Press

Teva Presents First Real-World Evidence Demonstrating Treatment with DuoResp Spiromax® Inhaler was Comparable to Symbico

Study Highlights Improved Outcomes for Asthma Patients Including Fewer Exacerbations Following Change in Treatment to DuoResp Spiromax(R) Teva Pharmaceuticals Europe B.V., today announced data from a ...
Nature

Skin Thickness in Children Treated With Daily or Periodical Inhaled Budesonide for Mild Persistent Asthma. The Helsinki Early Intervention Childhood Asthma Study

Inhaled corticosteroids (ICS) are recommended first-line treatment for all patients with persistent asthma (www.ginasthma.com, 1). However, ICS may have systemic effects. High doses of ICS may result ...
Manchester Evening News

AstraZeneca withdraws asthma drug

Drugs giant AstraZeneca is ending production of a pressurised metered dose inhaler version of its asthma treatment Pulmicort, which has been developed with technology partner SkyePharma.
Medscape

Bioavailability of the Budesonide Delivered by the Clickhaler and Turbuhaler Dry Powder Inhalers in Healthy Volunteers: A Pilot Study

This randomised, double-blind, double-dummy crossover study was designed to compare the pharmacokinetic profile and pulmonary bioavailability of budesonide 1000µg delivered by inhalation as a powder ...